抄録
Background/Aims: The presence of antibodies to the 210-kDa glycoprotein of the nuclear pore complex (gp210) is highly indicative of primary biliary cirrhosis (PBC). However, the significance of anti-gp210 antibody titers for monitoring PBC remains unresolved. Methods: We used an ELISA with a gp210 C-terminal peptide as an antigen to assess serum antibody titers in 71 patients with PBC. Results: Patients were classified into three groups: Group A in whom anti-gp210 titers were sustained at a high level, Group B in whom anti-gp210 status changed from positive to negative under ursodeoxycholic acid (UDCA) therapy, Group C in whom anti-gp210 antibodies were negative at the time of diagnosis. The rate of progression to end-stage hepatic failure was significantly higher in group A (60%) as compared to groups B (0%) and C (4.2%). The sustained antibody response to gp210 was closely associated with the severity of interface hepatitis. The significance of anti-gp210 antibody was confirmed by National Hospital Organization Study Group for Liver Disease in Japan. Conclusions: The serial quantitation of serum anti-gp210-C-terminal peptide antibodies is useful for monitoring the effect of UDCA and for the early identification of patients at high risk for end-stage hepatic failure.
| 元の言語 | 英語 |
|---|---|
| ページ（範囲） | 386-392 |
| ページ数 | 7 |
| ジャーナル | Journal of Hepatology |
| 巻 | 42 |
| 発行部数 | 3 |
| DOI | |
| 出版物ステータス | 出版済み - 3 2005 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Hepatology
これを引用
Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis. / Nakamura, Minoru; Shimizu-Yoshida, Yuki; Takii, Yasushi; Komori, Atsumasa; Yokoyama, Terufumi; Ueki, Toshihito; Daikoku, Manabu; Yano, Koji; Matsumoto, Takehiro; Migita, Kiyoshi; Yatsuhashi, Hiroshi; Ito, Masahiro; Masaki, Naohiko; Adachi, Hiroshi; Watanabe, Yukio; Nakamura, Yoko; Saoshiro, Takeo; Sodeyama, Takeshi; Koga, Michiaki; Shimoda, Shinji; Ishibashi, Hiromi.
：: Journal of Hepatology, 巻 42, 番号 3, 03.2005, p. 386-392.研究成果: ジャーナルへの寄稿 › 記事
}
TY - JOUR
T1 - Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis
AU - Nakamura, Minoru
AU - Shimizu-Yoshida, Yuki
AU - Takii, Yasushi
AU - Komori, Atsumasa
AU - Yokoyama, Terufumi
AU - Ueki, Toshihito
AU - Daikoku, Manabu
AU - Yano, Koji
AU - Matsumoto, Takehiro
AU - Migita, Kiyoshi
AU - Yatsuhashi, Hiroshi
AU - Ito, Masahiro
AU - Masaki, Naohiko
AU - Adachi, Hiroshi
AU - Watanabe, Yukio
AU - Nakamura, Yoko
AU - Saoshiro, Takeo
AU - Sodeyama, Takeshi
AU - Koga, Michiaki
AU - Shimoda, Shinji
AU - Ishibashi, Hiromi
PY - 2005/3
Y1 - 2005/3
N2 - Background/Aims: The presence of antibodies to the 210-kDa glycoprotein of the nuclear pore complex (gp210) is highly indicative of primary biliary cirrhosis (PBC). However, the significance of anti-gp210 antibody titers for monitoring PBC remains unresolved. Methods: We used an ELISA with a gp210 C-terminal peptide as an antigen to assess serum antibody titers in 71 patients with PBC. Results: Patients were classified into three groups: Group A in whom anti-gp210 titers were sustained at a high level, Group B in whom anti-gp210 status changed from positive to negative under ursodeoxycholic acid (UDCA) therapy, Group C in whom anti-gp210 antibodies were negative at the time of diagnosis. The rate of progression to end-stage hepatic failure was significantly higher in group A (60%) as compared to groups B (0%) and C (4.2%). The sustained antibody response to gp210 was closely associated with the severity of interface hepatitis. The significance of anti-gp210 antibody was confirmed by National Hospital Organization Study Group for Liver Disease in Japan. Conclusions: The serial quantitation of serum anti-gp210-C-terminal peptide antibodies is useful for monitoring the effect of UDCA and for the early identification of patients at high risk for end-stage hepatic failure.
AB - Background/Aims: The presence of antibodies to the 210-kDa glycoprotein of the nuclear pore complex (gp210) is highly indicative of primary biliary cirrhosis (PBC). However, the significance of anti-gp210 antibody titers for monitoring PBC remains unresolved. Methods: We used an ELISA with a gp210 C-terminal peptide as an antigen to assess serum antibody titers in 71 patients with PBC. Results: Patients were classified into three groups: Group A in whom anti-gp210 titers were sustained at a high level, Group B in whom anti-gp210 status changed from positive to negative under ursodeoxycholic acid (UDCA) therapy, Group C in whom anti-gp210 antibodies were negative at the time of diagnosis. The rate of progression to end-stage hepatic failure was significantly higher in group A (60%) as compared to groups B (0%) and C (4.2%). The sustained antibody response to gp210 was closely associated with the severity of interface hepatitis. The significance of anti-gp210 antibody was confirmed by National Hospital Organization Study Group for Liver Disease in Japan. Conclusions: The serial quantitation of serum anti-gp210-C-terminal peptide antibodies is useful for monitoring the effect of UDCA and for the early identification of patients at high risk for end-stage hepatic failure.
UR - http://www.scopus.com/inward/record.url?scp=13844289482&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=13844289482&partnerID=8YFLogxK
U2 - 10.1016/j.jhep.2004.11.016
DO - 10.1016/j.jhep.2004.11.016
M3 - Article
C2 - 15710222
AN - SCOPUS:13844289482
VL - 42
SP - 386
EP - 392
JO - Journal of Hepatology
JF - Journal of Hepatology
SN - 0168-8278
IS - 3
ER -